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Abstract
Introduction: Over the last few years the use of anabolic steroids has become increasingly common amongst
amateur athletes and for aesthetic purposes. As a result, the adverse events related to their use are being seen
more frequently. Methandrostenolone is an anabolic steroid which is widely available and has been used for both
performance enhancement and aesthetic purposes. This drug has also been reported to cause cholestasis of the
intra-hepatic bile ducts resulting in elevated aminotransferases, hyperbilirubinemia and clinical jaundice. However,
to the best of our knowledge this agent has not been previously reported to cause pancreatitis or acute kidney
injury.
Case presentation: In this paper, we report the case of a 50-year-old man of Indian descent who presented with
a six week history of diffuse abdominal pain, anorexia and weight loss following an eight week cycle of
methandrostenolone use. At initial presentation, his lipase level was 785 U/L, bilirubin was 922 μmol/L and
creatinine was 200 U/L while his aspartate aminotransferase and alanine aminotransferase levels were only mildly
elevated at 61 U/L and 56 U/L respectively. His lipase peaked on day nine at >3000 U/L whilst his creatinine level
was 299 U/L. Imaging was consistent with acute pancreatitis while a liver biopsy was consistent with intra-hepatic
cholestasis and a kidney biopsy revealed evidence of acute tubular necrosis.
Conclusion: Both acute pancreatitis and acute kidney injury have rarely been reported with anabolic steroid use
and they have not been previously reported to occur in the same patient. This case demonstrates some potentially
new and serious adverse consequences occurring with the use of anabolic steroids, of which physicians need to
be aware.
Introduction
Anabolic androgenic steroids (AAS) have been in wide-
spread use amongst elite athletes to enhance perfor-
mance for decades [1]. Major League Baseball and the
National Football League have provided numerous
examples of steroid use amongst their professional ath-
letes. Several Olympic athletes have tested positive for
the use of AAS or admitted to their use [2]. Meanwhile,
the Vancouver 2010 Winter Olympic games saw the
creation of the most sophisticated anti-doping testing
laboratory to date, resulting in 30 athletes testing
positive and being banned from attending the games
prior to their opening. With the knowledge of wide-
spread steroid use has come an increased awareness of
the adverse effects and sometimes serious consequences
of AAS use. Nevertheless, there seems to be an ever
increasing use of these agents by recreational athletes
and for aesthetic purposes. Recent estimates place AAS
use in the USA and Sweden at 1% of the population and
we can reasonably assume that the rates of use in
Canada are similar [1]. The internet has increased the
black market availability of these drugs without pre-
scription and consumers are frequently unaware of the
risks of taking these drugs.
Methandrostenolone (Dianab o l )w a sf i r s ti n t r o d u c e d
as an anabolic steroid by Ciba in the 1960s. Methan-
drostenolone was one of the AAS used to enhance
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pic program [3]. This agent has numerous side effects
common to anabolic androgenic steroids which include
gynecomastia, acne, mood changes (aggressiveness) and
testicular atrophy [4]. Stanozolol, another carbon-17-
alkylated anabolic steroid, has been previously reported
to cause severe cholestasis and acute renal failure in a
young athlete [5]. Acute kidney injury arising from the
use of anabolic steroids and vitamin supplementation in
two male athletes has also been recently reported [6].
Methandrostenolone has also been reported to cause
cholestasis of the intra-hepatic bile ducts resulting in
elevated aminotransferases, hyperbilirubinemia and clini-
cal jaundice [7]. In this paper, we present a case of pan-
creatitis, cholestasis of the liver and acute kidney injury
associated with the use of methandrostenolone for aes-
thetic purposes in a 50-year-old, non-athlete man.
A brief literature review of Medline and PubMed
Central, utilizing the search terms ‘androgenic anabolic
steroids’, ‘pancreatitis’ and ‘methandrostenolone’,f a i l e d
to reveal any other cases of pancreatitis arising from the
use of anabolic steroids.
Case presentation
A 50-year-old man of Indian descent, known to have
mild, chronic hepatitis C, presented with a two week his-
tory of diffuse abdominal pain. Six weeks prior to the
onset of the pain, he had a gradual onset of anorexia and
a 20 pound weight loss. Our patient noticed darkly
coloured urine and pale stools beginning around the time
of the onset of pain. He had not received treatment for
his hepatitis C infection. He had intermittent and occa-
sionally heavy alcohol consumption on weekends. He had
also been taking methandrostenolone: 10 mg orally twice
a day, five days a week for three weeks and then three
times a day, five days a week for the next five weeks, for a
total of eight weeks immediately prior to presentation.
When he presented, his white blood cell count was 9.8
giga/L (normal range 4.0-11.0 giga/L), his hemoglobin
level was 172 g/L (normal range 135-170 g/L) and his
platelet levels were 378 giga/L (normal range 150-400
giga/L). His lipase level was 785 U/L (normal range 0-
393 U/L), gamma-glutamyltransferase (GGT) level 24 U/
L (normal range 15-80 U/L), alkaline phosphatase (ALP)
level 154 U/L (normal range 50-160 U’L), total bilirubin
level 922 μmol/L (normal range 0-18 μmol/L), with
direct bilirubin 804 μmol/L (normal range 0-5 μmol/L),
alanine aminotransferase level (ALT) 56 U/L (normal
range 25-80 U/L), aspartate aminotransferase (AST)
level 61 U/L (normal range 10-38 U/L) and lactate
dehydrogenase level 242 U/L (normal range 90-210 U/
L). His international normalized ratio was 1.1 and
serum albumin level was 35 g/L (normal range 34-50 g/
L). He was also noted to have an element of acute renal
failure with a serum creatinine level of 200 μmol/L (nor-
mal range 60-115 μmol/L) (Table 1). He had no pre-
vious history of renal disease. He was admitted to our
hospital for supportive management and further
investigations.
A non-contrast computed tomography (CT) scan of
his abdomen was performed shortly after admission
which showed mild fatty infiltration of the liver. There
was no evidence of inflammatory fat stranding around
his pancreas or kidneys. An ultrasound of his abdomen
performed 48 hours later showed mild hepatic enlarge-
ment with his liver measuring 17.1 cm in length with a
coarse, echogenic texture. There were no focal hepatic
lesions or intra-hepatic duct dilatation. There was a
small amount of sludge in his gallbladder but no stones.
His common bile duct was of normal caliber at 2 mm
in diameter. His pancreas was well seen and unremark-
able. His renal parenchyma was echogenic and measured
at the upper limits of normal size which was in keeping
with medical renal disease.
Within a couple of days of admission, our patient
began to experience worsening nausea, vomiting and
abdominal pain. His serum lipase level declined over the
first three days, but it later began to rise and peaked on
day nine at > 3000 U/L, while his ALP level also peaked
on day eight at 206 U/L. His ALT and AST levels
remained only mildly elevated. Our patient’s creatinine
level rose to a peak of 299 μmol/L on day nine.
Serum auto-antibodies, serum protein electrophoresis
and cryoglobulins were all negative. Human immunode-
ficiency virus antibodies were negative however, as
anticipated, his hepatitis C viral RNA was qualitatively
positive. His fasting serum lipid levels were low with the
exception of triglycerides which were mildly elevated at
3.25 mmol/L (normal range 0.60-2.30 mmol/L). Our
patient’s clinical picture was most consistent with acute
pancreatitis and thus, a non-contrast (due to renal fail-
ure) CT scan of his abdomen was obtained on the tenth
day. This showed a bulky pancreas with adjacent inflam-
matory fat stranding which was interpreted as consistent
with pancreatitis without a focal drainable abscess.
There were also no signs of chronic pancreatitis.
Our patient went on to have a liver biopsy which
revealed grade 2 portal and lobular inflammation, stage
2-3 fibrosis consistent with hepatitis C viral infection,
moderately severe acute cholestasis consistent with ana-
bolic steroid use, and mild pericellular fibrosis consis-
tent with alcohol abuse but without evidence of
steatosis or steatohepatitis (Figure 1). A renal biopsy
was also performed which showed acute tubular injury
of uncertain etiology. His glomeruli were normal and
there was evidence of desquamation of his tubular
epithelial cells. Therefore, acute tubular necrosis was
confirmed as the etiology of his renal failure.
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began to resolve and he was asymptomatic at the time
of discharge. One month after discharge, his renal func-
tion had returned to normal and his amylase (46 U/L),
lipase (270 U/L), GGT (17 U/L), and ALP (128 U/L)
levels had all returned to normal. His total bilirubin
l e v e lr e m a i n e dm i l d l ye l e v a t e da t5 0μmol/L and his
ALT (84 U/L) and AST (67 U/L) levels were also mildly
elevated in keeping with his chronic hepatitis C
infection.
Discussion
A A Su s eo rm i s u s ei sn ol o n g e rs o l e l yb ye l i t ea t h l e t e s
seeking enhanced performance. Teenage boys in Sweden
reported using AAS for a variety of reasons [8], while
bodybuilders, weight-lifters and prison populations have
also been shown to have higher levels of misuse [9].
Our patient took AAS not for athletic performance but
for aesthetic reasons. He reported wanting to “remain in
shape” as the main reason for taking these pills. Ana-
bolic steroids are readily available to the general public
over the internet and at public gyms, they are easily
obtained illegally, without a prescription. As a result,
patients are less likely to report taking AAS to their
physician and physicians are less likely to consider the
p o s s i b i l i t yo ft h eu s eo fA A Si nt h en o n - a t h l e t e
population.
Our patient represents the first case of a patient devel-
oping pancreatitis as a result of anabolic androgenic
steroid use. A recent clinical workshop reviewed the cri-
teria necessary for reporting cases of Drug Induced
Liver Injury [10]. We believe that this case report meets
those criteria and we have reported on all of the
Table 1 Table showing laboratory values over time in hospital and in the first few weeks post discharge
WBC HGB BUN CR AMYLASE LIPASE GGT ALP BILI ALT AST
Admission 8.8 172 13.2 200 785 24 154 922 56 61
Post admission Day 1 12.5 148 11.9 175 634 13 133 755 45 51
Day 2 158 10.9 171 38 161 869 45 53
Day 3 10.8 160 11.3 185 71 968 10 135 739 33 42
Day 4 11.5 164 13.8 199 29 345 24 172 919 46 72
Day 5 16.7 290 47 417 18 182 937 48 67
Day 6 10.9 153 19.7 288 50 461 14 180 896 52 67
Day 7 13.9 170 24.5 298 141 1629 24 206 804 56 70
Day 8 16 161 24.3 291 1855 >3000 16 165 678 44 73
Day 9 14.1 136 26.4 299 1720 >3000 8 171 660 64 96
Day 10 17.1 137 22 246 841 >3000 8 151 544 47 54
Day 11 17.2 127 15 206 343 >3000 9 161 532 44 48
Day 12 15.8 121 12.3 179 9 159 473 35 45
Day 13 16.2 120 9.6 161 9 146 447 28 36
Day 14 18.7 123 9.4 153 9 119 424 27 38
Day 15 17.3 109 9 160 13 145 409 33 44
Day 16 20.7 111 7.9 136 13 122 302 24 31
Day 17 140 68 412 11 136 247 29 37
Day 18 18.6 112 5 120 14 1483 166 32 37
Discharge (Day 19) 13.5 102 5.1 131 13 130 136 33 37
At follow up
(Day 38)
11.8 131 4 119 64 237 23 145 53 92 59
(Day 39) 10.5 125 3.9 103 46 170 17 128 50 84 67
Figure 1 Liver cholestasis due to methandrostenolone.C o r e
liver biopsy showing bile filled canaliculi (black arrows) and bile in
the hepatocytes (white arrows). As well, there are plasma cells and
periportal inflammation.
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outlined in the summary document emanating from that
workshop. The usual causes of pancreatitis were
excluded in our patient. He did not have any evidence
of gallstones on repeated imaging studies, nor were his
alkaline phosphatase or GGT significantly elevated as
would be expected with obstructing gallstones. His tri-
glyceride levels were only mildly elevated and not to the
degree usually seen with pancreatitis. He had been hos-
pitalized for four days before the first sign of pancreati-
tis and had not consumed alcohol for at least a week at
that time. Given that his liver biopsy confirmed a chole-
static picture consistent with steroid use, we conclude
that this was the main contributing factor in the patho-
genesis of his pancreatitis. His hepatitis C may have
made him more prone to liver injury from steroid use
but the relatively low elevation of transaminases sug-
gests that his hepatitis C infection was quite mild and
stable. Furthermore, his liver biopsy showed a chole-
static pattern much more in keeping with steroid use
than hepatitis C infection.
Our patient’s acute kidney injury is unique in that the
pathology showed acute tubular necrosis (ATN). In two
previous case reports with anabolic steroid use and vita-
min supplementation as the cause of acute kidney injury,
the biopsies showed acute interstitial nephritis [6]. In
these cases, the kidney injury was attributed to the supple-
mentation of vitamin D with resultant hypercalcemia as
the mechanism of kidney injury. Excessive vitamin intake
and hypercalcemia were not factors in our patient. The
extremely high bilirubin level found in our patient is con-
sistent with a previously reported case of severe cholestasis
and ATN secondary to AAS use [5]. In that report, the
proposed mechanism of ATN was secondary to severe
cholestasis and the increased renal excretion of bilirubin.
Two additional cases of acute kidney injury associated
with the use of an over-the-counter nutritional supple-
ment (Superdrol™)h a v eb e e nr e p o r t e d[ 1 1 , 1 2 ] .I nt h e
first case a kidney biopsy was not performed, while the
second case reported a biopsy consistent with IgA nephro-
pathy [12]. Whatever the exact mechanism, our patient’s
history is most consistent with his AAS use as the main
culprit in both his acute kidney injury and pancreatitis.
Conclusion
AAS use and misuse is being seen in an expanding
population of patients because they are readily available
and often perceived as safe. The side effects and risks of
taking AAS are difficult to assess in controlled trials due
to the unethical nature of administering these drugs in
t h ed o s e su s u a l l yt a k e nb yp a t i e n t sw h ou s et h e mf o r
aesthetic or athletic purposes. As a result, with the
increasing use of these drugs, we can expect to see an
increase in previously unreported adverse consequences.
Although there have been previous reports of severe
cholestasis and jaundice with the recreational use of
anabolic steroids [13], this is the first case report where
acute pancreatitis and acute kidney injury also resulted
from such recreational use. Physicians need to be aware
of the risks to their patients who consume AAS, and to
consider that even with only mild elevations of amino-
transferases, serious consequences such as cholestasis,
acute kidney injury and pancreatitis may result.
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